Pfizer sets sights on R&D strategy amid modest FY25 results
Pfizer and investors alike look forward to further developments within the pharma’s newly acquired obesity portfolio. Image credit: ShU studio
Read MorePfizer and investors alike look forward to further developments within the pharma’s newly acquired obesity portfolio. Image credit: ShU studio
Read MoreEli Lilly announced plans to invest upwards of $3.5 billion to build a new injectable medicine and device manufacturing facility
Read MoreIn a move that underscores the pharmaceutical industry’s intensifying focus on technological transformation, Torrent Pharmaceuticals Limited has appointed Geena Malhotra
Read MorePharma M&A set to boom in 2026 January 31, 2026 | Saturday | Analysis | By Ayesha Siddiqui After years
Read MoreAs biotechnology platforms diversify and M&A reshapes pipelines and revenue streams, more pharmaceutical leaders are being measured by their ability
Read MoreThrough every era of modern pharma, PharmTech has been the voice for practical, real-world strategy. We make complex breakthroughs professionally
Read MoreGlobal pharmaceutical production experienced a surge in 2025, driven by front-loading activity as manufacturers accelerated global output ahead of anticipated
Read MoreThe projected fair value for Teva Pharmaceutical Industries is US$57.59 based on 2 Stage Free Cash Flow to Equity Teva
Read MoreWelcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In
Read MoreDublin, Jan. 22, 2026 (GLOBE NEWSWIRE) — The “Pharmaceutical Collaborative Robots Market – Global Industry Size, Share, Trends, Opportunity, and
Read More